血清HBeAg阴性慢性乙型肝炎患者APRI、FIB-4和血清TGF-β1水平变化*

doi:10.3969/j.issn.1672-5069.2020.06.011

Abstract

Abstract: Objective The aim of this study was to investigate the changes of ratio of aspartate aminotransferase to platelet counts (APRI), based on fibrosis-four (FIB-4) and serum transforming growth factor-β1 (TGF-β1) in patients with serum HBeAg negative chronic hepatitis B (CHB). Methods 78 patients with serum HBeAg-negative CHB and 78 healthy persons were enrolled in our hospital from January 2018 through May 2019, and the APRI, FIB-4 and serum TGF-β1 levels were detected or calculated. The liver biopsies were performed in all patients with CHB. Results The APRI score in patients with CHB was (0.9±0.4), which was significantly higher than that in the healthy group [(0.3±0.1), P<0.05] , the FIB-4 score was (1.4±0.4), significantly higher than [(0.5±0.2), P <0.05] in the healthy persons, and serum TGF-β1 level in patients with CHB was (14.5±5.3) ng / ml, which was significantly higher than [(7.4±3.5), P< 0.05] ng / ml in healthy persons; the APRI score in 33 patients with hepatic F0-1 fibrosis was (0.5±0.2), significantly lower than [(1.0±0.3),P<0.05] in 24 patients with F2, significantly lower than [1.3.±0.5), P<0.05】 in 12 patients with F3, and also significantly lower than [(1.8±1.6), P <0.05] in 9 patients with F4; the FIB-4 score in patients with F0-1 was (0.9±0.3), significantly lower than [(1.5±0.4), P < 0.05] in patients with F2, significantly lower than [(1.9±0.4), P <0.05] in patients with F3, and also significantly lower than [(3.2±0.6), P <0.05] in patients with F4; the serum TGF-β1 level in patients with F0-1 was (9.7±3.6) ng / ml, which was significantly lower [(10.5±4.4) ng / ml, P<0.05] in patients with F2, significantly lower than [(15.8±5.9) ng / ml, P<0.05] in patients with F3, and also significantly lower than [(19.5±6.2) ng / ml, P<0.05] in patients with F4. Conclusion The APRI and FIB-4 scores as well as serum TGF-β1 levels in serum HBeAg-negative patients with CHB increase greatly, which might help improve the diagnostic accuracy of liver fibrosis in this setting.

Key words: Chronic hepatitis B, Liver fibrosis, Ratio of aspartate aminotransferase to platelet count, Transforming growth factor-β1

Tang Pingyang, Wang Jiebing, Zhang Xiaolan, et al. Changes of APRI and FIB-4 scores in patients with serum HBeAg-negative chronic hepatitis B[J]. Journal of Practical Hepatology, 2020, 23(6): 801-804.

References

[1] Barroeta A B, Simonetti S, Vitale S, et al. GM - CSF inhibits c -kit and scf expression by bone marrow-derived dendritic cells. Front Immunol, 2017, 8(1): 146-147.
[2] Parikh P, Ryan J D, Tsochatzis E A, et al. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection . Ann Transl Med, 2017, 5(3): 40 -53.
[3] Xu Y, Tang X P, Zhang Y H, et al. Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample. Hepatology, 2015, 62(6): 1731–1741.
[4] 程渝, 郭锐, 刘明国, 等. MRI与血清学定量指标检测对肝纤维化的诊断价值. 中华实用诊断与治疗杂志, 2018, 32(6):589-593.
[5] 闫蓉, 高保华, 田秋梅, 等. RPR FIB-4 APRI及AAR对107例慢性乙型肝炎肝纤维化的诊断准确性比较. 中国实用内科杂志, 2019, 39(3):249-253.
[6] 刘红, 吴疆. 国内外慢性乙型肝炎防治指南比较:抗病毒治疗诊断标准和治疗方案. 中国肝脏病杂志(电子版), 2018, 10(1):10-17.
[7] Luo H, Zhang X X, Cao L H, et al. Serum hepatitis b virus rna is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis b patients. World J Gastroenterol, 2019, 25(6): 719–728.
[8] Joshua D R, Ryan E, Robert H M, et al. Hepacivirus a infection in horses defines distinct envelope hypervariable regions and elucidates potential roles of viral strain and adaptive immune status in determining envelope diversity and infection outcome. J Virol, 2018 , 92(18): 14-18.
[9] Motta M, Sejal M, Márcio T N, et al. A novel hepacivirus in wild rodents from south america. Viruses, 2019 ,11(3): 296-297.
[10] 李军, 陈攀, 陈孝, 等. 以DJ-1蛋白为靶点治疗肝纤维化的研究进展. 中国药理学通报, 2018, 34(3):309-312.
[11] Yan J, Kim E M, Choi M H, et al. Significance of serology by multi-antigen elisa for tissue helminthiases in Korea. J Korean Med Sci, 2017,32(7): 1118–1123.
[12] Liao R, Fu Y P, Wang T, et al. Metavir and fib-4 scores are associated with patient prognosis after curative hepatectomy in hepatitis B virus-related hepatocellular carcinoma: a retrospective cohort study at two centers in China. Oncotarget, 2017 , 8(1): 1774–1787.
[13] Sarin S K, Kumar M, Lau G K, et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 2016 ,10(1): 1–98.
[14] Tong M J, Pan C Q, Han S H, et al. An expert consensus for the management of chronic hepatitis b in Asian Americans. Aliment Pharmacol Ther,2018 ,47(8): 1181–1200.
[15] Elia M C, Robert T S, Julia P A, et al. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis b patients. World J Gastroenterol, 2018, 24(17): 1825–1838.
[16] 金彩婷,郭利伟,梁伟峰. 慢性乙型病毒性肝炎肝纤维化无创性血清诊断指标研究进展. 中华实验和临床感染病杂志(电子版), 2018, 12(1):11-14.
[17] Zhang G L, Zhao Q Y, Lin C S, et al. Transient elastography and ultrasonography: optimal evaluation of liver fibrosis and cirrhosis in patients with chronic hepatitis B concurrent with nonalcoholic fatty liver disease. Biomed Res Int, 2019, 20(1): 3951-3957.
[18] Yan L T, Wang L L, Yao J, et al. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis b virus infection. Medicine (Baltimore), 2020, 99(8): 19248-19249.
[19] Xu S H, Li Q , Hu Y P, et al. Development of a model based on biochemical, real-time tissue elastography and ultrasound data for the staging of liver fibrosis and cirrhosis in patients with chronic hepatitis B. Mol Med Rep, 2016, 14(4): 3609-3619.
[20] Mak L Y, Danny K H, Cheung K S, et al. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol, 2018, 9(6): 163-164.
[21] Sadhna D, Stephen C W, Swan N T, et al. Liver pathology of hepatitis C, beyond grading and staging of the disease. World J Gastroenterol, 2016, 22(4): 1357–1366.
[22] Maria P S, Barbara K M, Małgorzata A, et al. Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C. BMC Infect Dis, 2017, 17(1): 355-361.
[23] Wu N, Meng F y, Zhou T H, et al. The secretin/secretin receptor axis modulates ductular reaction and liver fibrosis through changes in transforming growth factor-β1–mediated biliary senescence. Am J Pathol, 2018, 188(10): 2264–2280.
[24] Liu N, Feng J, Lu X Y, et al. Isorhamnetin inhibits liver fibrosis by reducing autophagy and inhibiting extracellular matrix formation via the tgf-β1/smad3 and tgf-β1/p38 mapk pathways. Mediators Inflamm, 2019, 20(1): 617-619.
[25] Min H J, Ka Y H, Ji H P, et al. New mechanism of hepatic fibrogenesis: hepatitis c virus infection induces transforminggrowth factor β1 production through glucose-regulated protein 94. J Virol, 2016, 90(6): 3044–3055.

Changes of APRI and FIB-4 scores in patients with serum HBeAg-negative chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Ruiqing,Yuan Xiaopeng. Mechanism of hypoxia inducible factor-1α involving in liver fibrosis [J]. Journal of Practical Hepatology, 2021, 24(1): 145-148.
[2]	Song Yeyu, Fan Jiangao. Diagnosis and treatment of sarcopenic obesity with fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 149-152.
[3]	Zhan Aiqin, Chen Chunli, Zhu Qingfeng, et al. Therapeutic effect of isoglycyrrhizic acid magnesium in treatment of patients with hepatitis B and dynamic changes of Treg 17 cells and related cytokines [J]. Journal of Practical Hepatology, 2020, 23(6): 793-796.
[4]	Liu Di, Dong Xin, Yang Jianjun, et al. Application of transient elastography and portal hemodynamic parameters in the diagnosis of liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2020, 23(6): 797-800.
[5]	Cui Luyao, Yuan Xiwei, Liu Lingdi, et al. Diagnostic values of plasma Golgi protein 73 and liver stiffness measurement combination for liver fibrosis in patients with hepatitis B and C [J]. Journal of Practical Hepatology, 2020, 23(6): 809-812.
[6]	Zhang Hao, Chang Jiandong, Chen Xiaoyan.. Diagnostic value of ultrasonic elastography combined with serological indexes in evaluation of liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2020, 23(5): 642-645.
[7]	Li Na, Zheng Shaoqiu, Zhao Shousong. Application of FibroScan, APRI,FIB-4 and GPR in prediction of esophageal varices in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2020, 23(4): 560-563.
[8]	Chen Lili, Fu Maoxiong, Meng Xubiao, et al. Clinical value of fasting C-peptide in assessing the progression of liver fibrosis in patients with NAFLD and T2DM [J]. Journal of Practical Hepatology, 2020, 23(1): 38-41.
[9]	Sun Hongju, Wang Yanyan, Xu Congcong, et al. Efficacy of tiopronin and metoprolol combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2020, 23(1): 54-57.
[10]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[11]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[12]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[13]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[14]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[15]	Cheng Hua, Ju Hui, Song Deshun et al. Value of serum angiopoietin-like protein 2 and Golgi protein 73 levels in the diagnosis of hepatic fibrosis in patient with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 494-497.